- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 07.01. | Arrowhead showcases early obesity data; Instil bails on PD-1/VEGF drug | ||
| 07.01. | 5 FDA decisions to watch in the first quarter of 2026 | ||
| 06.01. | Alumis soars as TYK2 drug hits mark in psoriasis trials | ||
| 06.01. | Amgen buys protein-degrading startup Dark Blue for up to $840M | ||
| 06.01. | CDC, following Trump's orders, weakens US stance on childhood vaccinations | ||
| 05.01. | Surfing the AI wave: How pharma can harness agents in ERP | ||
| 05.01. | Moderna, searching for a rebound, to seek approval of mRNA flu shot | ||
| 05.01. | Zenas shares crash after top drug misses expectations in immune disease study | ||
| 05.01. | Novo launches Wegovy pill; Argenx to swap CEOs | ||
| 05.01. | Strategic diagnostic testing partnerships are accelerating clinical research | ||
| 05.01. | 10 clinical trials to watch in the first half of 2026 | ||
| 23.12.25 | Novo Nordisk's weight loss pill approved by FDA | ||
| 23.12.25 | Biopharma CEO optimism is wavering in the US | ||
| 22.12.25 | Biopharma climbs higher as 9 drugmakers ink 'pandering' drug price deals with Trump | ||
| 22.12.25 | Radiopharmaceutical specialist Aktis seeks an IPO | ||
| 22.12.25 | Cytokinetics set to battle Bristol Myers as FDA approves heart drug | ||
| 19.12.25 | Patient deaths put Merck, Daiichi's ADC trial on partial hold | ||
| 19.12.25 | Galapagos TYK2 drug hits goal in one trial, misses in another | ||
| 19.12.25 | BioMarin to buy rare disease drugmaker Amicus for $4.8B | ||
| 19.12.25 | Novo files for CagriSema approval; Merck and Pfizer's trial win | ||
| 18.12.25 | Moderna gets funding for H5 pandemic influenza vaccine | ||
| 18.12.25 | Lilly obesity pill, headed for quick FDA review, hits mark in 'maintenance' trial | ||
| 18.12.25 | Insmed's 'win streak' ends as top drug fails study in chronic nasal condition | ||
| 18.12.25 | Takeda says $4B TYK2 drug succeeds in large psoriasis studies | ||
| 18.12.25 | Orum, a biotech marrying ADCs with protein degraders, captures $100M in funding |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .